Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Non-Squamous Non-Small Cell Carcinoma: full-pipeline trial registry
2 of 6 indexed Lung Non-Squamous Non-Small Cell Carcinoma trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Lung Non-Squamous Non-Small Cell Carcinoma: 6 US clinical trials tracked, 2 recruiting.
Lung Non-Squamous Non-Small Cell Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition lung-non-squamous-non-small-cell-carcinoma
OPEN 2 | RECR 33% | LATE 3 | EARLY 2 | RANK #2866 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Lung Non-Squamous Non-Small Cell Carcinoma lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lung Non-Squamous Non-Small Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lung Non-Squamous Non-Small Cell Carcinoma is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lung Non-Squamous Non-Small Cell Carcinoma research.
National Cancer Institute (NCI) accounts for 5 of 6 trials (83.3%). 2 distinct sponsors appear on at least one study for this condition label.
-
Typical Lung Non-Squamous Non-Small Cell Carcinoma enrolment sits around 390 participants.
Median target enrolment is 390 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Lung Non-Squamous Non-Small Cell Carcinoma research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
National Cancer Institute (NCI)
NCT04267848
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05198830
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03793179
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
NCT02193282
Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03737994
Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity
Ohio State University Comprehensive Cancer Center
NCT04954885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lung Non-Squamous Non-Small Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lung Non-Squamous Non-Small Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lung Non-Squamous Non-Small Cell Carcinoma page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Lung Non-Squamous Non-Small Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Lung Non-Squamous Non-Small Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Non-Squamous Non-Small Cell Carcinoma condition card totals 6 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.